hVIVO PLC Exercise of Options (9249T)

TIDMHVO

RNS Number : 9249T

hVIVO PLC

23 March 2023

hVIVO plc

("hVIVO" or the "Company")

Exercise of Options

hVIVO plc (AIM: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, confirms that it has issued 7,716,964 new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options by a former employee of the Company. It is expected that the admission of the Ordinary Shares will occur on 28 March 2023.

Following admission, the Company will have 678,764,735 Ordinary Shares in issue. This figure of 678,764,735 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

 
 hVIVO plc                                                                            [phone] 
 Yamin 'Mo' Khan, Chief Executive Officer 
  Stephen Pinkerton, Chief Financial Officer 
 
 Liberum Capital (Nominated Adviser and Joint Broker)                                 [phone] 
 Ben Cryer, Edward Mansfield, Phil Walker, Will King 
 
 finnCap plc (Joint Broker)                                                           [phone] 
 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM) 
 
 Davy (Euronext Growth Adviser and Joint Broker)                                       [phone] 
 Anthony Farrell, Niall Gilchrist 
 
 Walbrook PR (Financial PR & IR)                              [phone] or [e-mail] 
  Stephanie Cuthbert / Phillip Marriage /                    [phone] / [phone] / 
  Louis Ashe-Jepson                                                                   [phone] 
 
 

Notes to Editors

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEPPUQAWUPWGMP

(END) Dow Jones Newswires

March 23, 2023 03:00 ET (07:00 GMT)